JPH0196121A - Remedy for hyperkeratosis - Google Patents
Remedy for hyperkeratosisInfo
- Publication number
- JPH0196121A JPH0196121A JP62250776A JP25077687A JPH0196121A JP H0196121 A JPH0196121 A JP H0196121A JP 62250776 A JP62250776 A JP 62250776A JP 25077687 A JP25077687 A JP 25077687A JP H0196121 A JPH0196121 A JP H0196121A
- Authority
- JP
- Japan
- Prior art keywords
- shogaol
- drug
- formula
- hyperkeratosis
- remedy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010020649 Hyperkeratosis Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 16
- 208000001126 Keratosis Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 2
- 235000002780 gingerol Nutrition 0.000 claims description 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 abstract description 29
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 244000273928 Zingiber officinale Species 0.000 abstract description 3
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000008397 ginger Nutrition 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 239000001841 zingiber officinale Substances 0.000 abstract description 2
- 239000003390 Chinese drug Substances 0.000 abstract 1
- 241000234314 Zingiber Species 0.000 abstract 1
- 230000003631 expected effect Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000003826 tablet Substances 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000008187 granular material Substances 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- -1 fluidity promoters Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010243 sho-seiryu-to Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、(6)−ショウガオール[(6)−shog
aol]を有効成分とする角化症治療剤に関するもので
ある。Detailed Description of the Invention [Industrial Field of Application] The present invention provides (6)-shogaol [(6)-shog
The present invention relates to a therapeutic agent for keratosis containing AOL] as an active ingredient.
[従来の技術および問題点]
乾癖に代表される角化症は近年増加傾向にあり、特に乾
癖においては、病巣部皮膚の主な形態学的変化として著
しく元通した表皮細胞のターン・オーバーに基づく表皮
細胞層の肥厚と角化異常、ならびに表皮乳頭層の炎症反
応や表皮細胞層への多核白血球遁走が挙げられる。[Prior art and problems] Keratosis, represented by psoriasis, has been on the rise in recent years, and in psoriasis in particular, the main morphological changes in the skin at the lesion site are the remarkable reversal of epidermal cell turns and These include hypertrophy of the epidermal cell layer and abnormal keratosis due to overgrowth, as well as inflammatory reactions in the papillary epidermal layer and fugue migration of polynuclear leukocytes to the epidermal cell layer.
現在まで、この角化症の治療剤としてステロイド剤が使
用されているが、重篤な副作用が問題となっている。ま
たビタミンA誘導体(レチノイド)は催奇形性の問題か
ら使用が制限されており、従来、この角化症のための画
期的な治療薬は存在しなかった。Until now, steroids have been used as therapeutic agents for this keratosis, but serious side effects have become a problem. Further, the use of vitamin A derivatives (retinoids) is restricted due to the problem of teratogenicity, and to date, there has been no innovative therapeutic agent for this keratosis.
[問題点を解決するための手段]
本発明者等は、この角化症に有効な薬剤を開発すべく鋭
意検討した結果、(6)−ショウガオールが角化症の治
療に対し優れた効果を有することを見出し、これに基づ
いて本発明を完成するに到った。[Means for solving the problem] As a result of intensive studies to develop a drug effective for this keratosis, the present inventors found that (6)-shogaol has an excellent effect on the treatment of keratosis. Based on this finding, the present invention has been completed.
すなわち、本発明は、下記式
で表される(6)−ショウガオール[1−(4−ヒドロ
キシ−3−メトキシフェニル)−(E )−4−デセン
−3−オン]を有効成分とする角化症治療剤(以下、。That is, the present invention provides a horn containing as an active ingredient (6)-shogaol [1-(4-hydroxy-3-methoxyphenyl)-(E)-4-decen-3-one] represented by the following formula. Anti-inflammatory agent (hereinafter referred to as
本発明の薬剤という)である。(referred to as the drug of the present invention).
本発明の薬剤の有効成分である(6)−ショウガオール
は、たとえば漢方薬である柴胡佳枝乾美湯、小青竜湯ま
たは葛根湯などに配剤されている漢薬、乾美あるいは生
美に含まれる成分で中枢抑制作用、鎮痛作用等を有する
ことが知られている。(6)-Shogaol, which is the active ingredient of the drug of the present invention, is used in the Chinese medicine, Kenbi or Nakumi, which is used in the Chinese herbal medicines such as Saiko Kae Kenbito, Shoseiryuto or Kakkonto. The ingredients contained in it are known to have central depressant effects, analgesic effects, etc.
この(6)−ショウガオールは、例えば以下のようにし
て得ることができる。This (6)-shogaol can be obtained, for example, as follows.
ショウガの乾燥根茎を、エーテル、エタノール、メタノ
ール等の有機溶媒で抽出して抽出エキスを得、これをシ
リカゲルを担体としたカラムクロマトグラフィーに付し
、n−ヘキサン、アセトン、ベンゼン、酢酸エチル等の
有機溶媒の単独または混合溶媒で展開して(6)−ショ
ウガオールを含有する分画を得、これを更に分取薄層ク
ロマトグラフィーに付して精製することにより得ること
ができる。Dried rhizomes of ginger are extracted with organic solvents such as ether, ethanol, methanol, etc. to obtain an extract, which is subjected to column chromatography using silica gel as a carrier. It can be obtained by developing with an organic solvent alone or a mixture thereof to obtain a fraction containing (6)-shogaol, which is further purified by preparative thin layer chromatography.
以下に(6)−ショウガオールの製造の具体例を示す。A specific example of the production of (6)-shogaol is shown below.
[具体例コ
ショウガ(Zingiber officinale
Roscoe)の乾燥根茎2 kgを粉砕し、エーテル
3Qで7時間還流抽出した。抽出残渣を更にエーテル3
Qで2回、7時間還流抽出した。以上の抽出液を合併し
、減圧下でエーテルを除去して抽出エキス77.059
を得た。[Specific example: Zingiber officinale
2 kg of dried rhizomes of P. roscoe were ground and extracted under reflux with ether 3Q for 7 hours. The extraction residue is further diluted with ether 3
Reflux extraction was carried out with Q twice for 7 hours. Combine the above extracts, remove the ether under reduced pressure, and extract 77.059
I got it.
このエーテル抽出エキス77.059をシリカゲル70
09(Merck社製、Kieselgel 60)を
用いたカラムクロマトグラフィーに付し、n−ヘキサン
とエーテルの混合溶媒でエーテルの割合を順次増加しな
がら展開した。Add this ether extract 77.059 to 70% silica gel.
09 (manufactured by Merck, Kieselgel 60) and developed with a mixed solvent of n-hexane and ether while increasing the proportion of ether.
n−ヘキサン:エーテル(70:30)O,flで溶出
したフラクションとn−ヘキサン:エーテル(60:4
0)1,612で溶出したフラクションを合併し、溶媒
除去して13.69の残渣を得た。この残渣を、再度シ
リカゲルを用いたカラムクロマトグラフィーに付し、n
−ヘキサン:エーテル(95:5)で溶出したフラクシ
ョンを分取し、溶媒除去して得た残渣5.489を分取
薄層クロマトグラフィー[プレート、kieselge
l 60 P F ts+;展開溶媒。The fraction eluted with n-hexane:ether (70:30) O, fl and the fraction eluted with n-hexane:ether (60:4)
0) The fractions eluted at 1,612 were combined and the solvent removed to give a residue of 13.69. This residue was again subjected to column chromatography using silica gel, and n
- The fraction eluted with hexane:ether (95:5) was collected, and the residue obtained by removing the solvent was subjected to preparative thin layer chromatography [plate, kieselge
l 60 P F ts+; developing solvent.
n−ヘキサン:アセトン(7:3)]に付し淡黄色油状
物質80:19(収率0.04%)を得た。この淡黄色
油状物質の理化学的性質は文献記載の(6)−ショウガ
オールの理化学的性質と一致した。n-hexane:acetone (7:3)] to give a pale yellow oily substance 80:19 (yield 0.04%). The physicochemical properties of this pale yellow oily substance were consistent with those of (6)-shogaol described in the literature.
次に、本発明の薬剤の有効成分である(6)−ショウガ
オールが角化症治療作用を有することを実験例を挙げて
説明する。Next, the fact that (6)-shogaol, which is the active ingredient of the drug of the present invention, has a therapeutic effect on keratosis will be explained using experimental examples.
[実験例]
表皮細胞増殖因子(EGF)に対する増殖抑制作用24
穴プレートに線維芽細胞(balb/c 3T3cel
1g)を0.5−中に2.5xlO’個含むように調製
したlO%仔牛血清を含む培養液(以下、C8DMEM
と称する)を1穴あたり0.5−ずつ注入した。[Experiment example] Growth inhibitory effect on epidermal growth factor (EGF) 24
Fibroblast cells (BALB/c 3T3cell
A culture solution containing 10% calf serum (hereinafter referred to as C8DMEM) prepared to contain 2.5
) was injected at a rate of 0.5 - per hole.
線維芽細胞が単層状態で飽和になった後、1%C3DM
EMにかえ、12時間37℃、5%CO,で培養し、(
6)−ショウガオール、E G F (Collabo
rativeresearch、 Inc、製)それぞ
れ25成を添加してさらに16時間培養した。これに
0 、5 μci1507J/wellの3H−チミジ
ンを加えて8時間培養した後、培養液を除去し、冷却し
た含生理食塩リン酸緩衝液にて洗浄し、5%冷トリクロ
ロ酢酸を加え30分間放置した。上清を除去後、0.5
M水酸化ナトリウム水溶液に溶解し、0.5M塩酸で中
和し、液体シンチレーションカウンターでカウントした
。この増殖に伴って細胞内に取り込まれた’H−チミジ
ンの放射活性を測定し細胞増殖に対する(6)−ショウ
ガオールの作用を検討した。その結果、EGFによって
増殖が促進されたbalb/c 3T3細胞に対し、5
2,7%の増殖抑制が認められた。After fibroblasts were saturated in monolayer, 1% C3DM
Change to EM and culture at 37°C, 5% CO for 12 hours (
6)-Shogaol, EGF (Collabo
(manufactured by Rativeresearch, Inc.) were added to the cells, and the cells were further cultured for 16 hours. After adding 3H-thymidine at 0 and 5 μci 1507 J/well and culturing for 8 hours, the culture medium was removed and washed with cooled saline-containing phosphate buffer, and 5% cold trichloroacetic acid was added for 30 minutes. I left it alone. After removing the supernatant, 0.5
It was dissolved in M aqueous sodium hydroxide solution, neutralized with 0.5 M hydrochloric acid, and counted using a liquid scintillation counter. The effect of (6)-shogaol on cell proliferation was investigated by measuring the radioactivity of 'H-thymidine incorporated into cells as the cells proliferated. As a result, for BALB/c 3T3 cells whose proliferation was promoted by EGF, 5
A 2.7% growth inhibition was observed.
この結果から、(6)−ショウガオールにすぐれた角化
症治療作用があることが確認された。From this result, it was confirmed that (6)-shogaol has an excellent keratosis therapeutic effect.
次に、(6)−ショウガオールの急性毒性試験をIcR
系雄性マウスを用いて行ったところ、LD、oは静脈内
投与で50 、9 m9 /に9 (up and d
own法)、経口投与で68719/に9 (Litc
hfield−Wilcoxon法)であった。Next, the acute toxicity test of (6)-shogaol was performed using IcR.
When conducted using male mouse strains, LD, o was 50,9 m9/9 (up and d) by intravenous administration.
own method), oral administration 68719/9 (Litc
hfield-Wilcoxon method).
このように、(6)〜ショウガオールは毒性が低く、安
全性の高いものである。Thus, (6) - shogaol has low toxicity and high safety.
次に、本発明の薬剤の有効成分である(6)−ショウガ
オールの投与量および製剤化について説明する。Next, the dosage and formulation of (6)-shogaol, which is the active ingredient of the drug of the present invention, will be explained.
本発明の化合物はそのまま、あるいは慣用の製剤担体と
共に動物および人に投与することができろ。投与形態と
しては、特に限定がなく、必要に応じ適宜選択して使用
され、錠剤、カプセル剤、顆粒剤、細粒剤、散剤等の経
口剤、注射剤、坐剤等の非経口剤が挙げられる。The compounds of this invention can be administered to animals and humans either neat or with conventional pharmaceutical carriers. The dosage form is not particularly limited and may be selected and used as necessary, and may include oral dosage forms such as tablets, capsules, granules, fine granules, and powders, and parenteral dosage forms such as injections and suppositories. It will be done.
経口剤として所期の効果を発揮するためには、11者の
年令、体重、疾患の程度により異なるが、通常成人で(
6)−ショウガオールの重量として20〜80〜を、1
日数回に分けての服用が適当と思われる。In order for an oral drug to have the desired effect, it usually takes an adult drug (
6) - 20 to 80 ~ as the weight of gingerol, 1
It seems appropriate to take the drug in divided doses several times a day.
本発明において錠剤、カプセル剤、顆粒剤等の経口剤は
、例えばデンプン、乳糖、白糖、マンニット、カルボキ
シメチルセルロース、コーンスターチ、無機塩類等を用
いて常法に従って製造される。In the present invention, oral preparations such as tablets, capsules, and granules are manufactured according to conventional methods using, for example, starch, lactose, sucrose, mannitol, carboxymethyl cellulose, cornstarch, inorganic salts, and the like.
この種の製剤には、適宜前記賦形剤の他に、結合剤、崩
壊剤、界面活性剤、滑沢剤、流動性促進剤、矯味剤、着
色剤、香料等を使用することができる。それぞれの具体
例は以下に示す如くである。In addition to the excipients mentioned above, binders, disintegrants, surfactants, lubricants, fluidity promoters, flavoring agents, coloring agents, fragrances, and the like can be used in this type of preparation as appropriate. Specific examples of each are shown below.
[結合剤コ
デンプン、デキストリン、アラビアゴム末、ゼラチン、
ヒドロキシプロピルスターチ、メチルセルロース、カル
ボキシメチルセルロースナトリウム、ヒドロキシプロピ
ルセルロース、結晶セルロース、エチルセルロース、ポ
リビニルピロリドン、マクロゴール。[Binder co-starch, dextrin, gum arabic powder, gelatin,
Hydroxypropyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone, macrogol.
[崩壊剤コ
デンプン、ヒドロキシプロピルスターチ、カルボキシメ
チルセルロースナトリウム、カルボキシメチルセルロー
スカルシウム、カルボキシメチルセルロース、低置換ヒ
ドロキシプロピルセルロース。[Disintegrant co-starch, hydroxypropyl starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, low substituted hydroxypropyl cellulose.
[界面活性剤]
ラウリル硫酸ナトリウム、大豆レシチン、ショ糖脂肪酸
エステル、ポリソルベート 80゜[滑沢剤]
タルク、ロウ類、水素添加植物油、ショ糖脂肪酸エステ
ル、ステアリン酸マグネシウム、ステアリン酸カルシウ
ム、ステアリン酸アルミニウム、ポリエチレングリコー
ル。[Surfactant] Sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, polysorbate 80° [Lubricant] Talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, Polyethylene glycol.
[流動性促進剤]
軽質無水ケイ酸、乾燥水酸化アルミニウムゲル、合成ケ
イ酸アルミニウム、ケイ酸マグネシウム。[Fluidity promoter] Light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate.
また、本発明の薬剤は、懸濁液、エマルジョン剤、ノロ
ツブ剤、エリキシル剤としても投与することができ、こ
れらの各種剤形には、矯味矯臭剤、着色剤を含有しても
よい。The drug of the present invention can also be administered as a suspension, emulsion, tablet, or elixir, and these various dosage forms may contain flavoring agents and coloring agents.
非経口剤として所期の効果を発揮するためには、小者の
年令、体重、疾患の程度により異なるが、通常成人で(
6)−ショウガオールの重量として1日0.25〜1(
M9までの静注、点滴静注、皮下注射、筋肉注射が適当
と思われる。In order for a parenteral drug to have the desired effect, it usually depends on the child's age, weight, and degree of disease, but it is usually administered in adults (
6) - 0.25 to 1 (by weight of shogaol) per day
Intravenous injection up to M9, intravenous drip, subcutaneous injection, and intramuscular injection are considered appropriate.
この非経口剤は常法に従って製造され、希釈剤として一
般に注射用蒸留水、生理食塩水、ブドウ糖水溶液、注射
用植物油、ゴマ油、ラッカセイ油、ダイズ油、トウモロ
コシ油、プロピレングリコール、ポリエチレングリコー
ル等を用いることができる。さらに必要に応じて、殺菌
剤、防腐剤、安定剤を加えてもよい。また、この非経口
剤は安定性の点から、バイアル等に充填後冷凍し、通常
の凍結乾燥技術により水分を除去し、使用直前に凍結乾
燥物から液剤を再調製することもできる。更に、必要に
応じて適宜、等張化剤、安定剤、防腐剤、無痛化剤等を
加えても良い。This parenteral preparation is manufactured according to a conventional method, and generally uses distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, polyethylene glycol, etc. as a diluent. be able to. Furthermore, a bactericide, a preservative, and a stabilizer may be added as necessary. In addition, from the viewpoint of stability, this parenteral preparation may be filled into a vial or the like, then frozen, water removed by ordinary freeze-drying techniques, and a liquid preparation prepared from the freeze-dried product immediately before use. Furthermore, isotonizing agents, stabilizers, preservatives, soothing agents, etc. may be added as appropriate.
その他の非経口剤としては、外用液剤、軟膏等の塗布剤
、直腸内投与のための坐剤等が挙げられ、常法に従って
製造される。Other parenteral preparations include liquid preparations for external use, liniments such as ointments, suppositories for rectal administration, and the like, which are manufactured according to conventional methods.
以下に実施例を挙げてさらに詳しく説明するが、本発明
はこれによりなんら制限されるものではない。The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.
実施例1
■コーンスターチ 23.59■結晶セルロー
ス tsg
■カルボキシメチル
セルロースカルシウム 5g
■軽質無水ケイ酸 0.59■ステアリン酸
マグネシウム 19
66−ショウガオール 5
計 509
上記の処方に従って■〜■を均一に混合し、打鍵機にて
圧縮成型して一部200π9の錠剤を得た。Example 1 ■Corn starch 23.59■Crystalline cellulose tsg ■Carboxymethylcellulose calcium 5g ■Light anhydrous silicic acid 0.59■Magnesium stearate 19 66-shogaol 5 Total 509 Mix ■~■ uniformly according to the above recipe, Compression molding was performed using a key press to obtain some tablets of 200π9.
この錠剤−錠には、(6)−ショウガオール20mgが
含有されており、成人1日1〜4錠を数回にわけて服用
する。This tablet contains 20 mg of (6)-shogaol, and adults should take 1 to 4 tablets a day in several doses.
実施例2
■結晶セルロース 39.59■ステアリン酸
マグネシウム 0.5g■カルボキシメチル
セルロースカルシウム 59
6−ショウガオール 5
計 509
上記の処方に従って■、■および■の一部を均一に混合
し、圧縮成型した後、粉砕し、■および■の残量を加え
て混合し、打錠機にて圧縮成型して一部200 JI9
の錠剤を得た。Example 2 ■ Crystalline cellulose 39.59 ■ Magnesium stearate 0.5 g ■ Calcium carboxymethyl cellulose 59 6-shogaol 5 Total 509 After uniformly mixing ■, ■, and part of ■ according to the above recipe and compression molding. , crushed, added the remaining amounts of ■ and ■, mixed, compressed with a tablet machine, and made a portion of 200 JI9
tablets were obtained.
この錠剤−錠には、(6)−ショウガオール20yrg
が含有されており、成人1日1〜4錠を数回にわけて服
用する。This tablet contains (6)-shogaol 20yrg
It contains 1 to 4 tablets per day for adults, divided into several doses.
実施例3
■結晶セルロース 179
■10%ヒドロキシプロピル
セルロースエタノール溶液 259
■カルボキシメチル
セルロースカルシウム 2.79
■ステアリン酸マグネシウム 0.396−ショウガオ
ール 5
計 509
上記の処方に従って■、■および■を均一に混合し、常
法によりねつ和し、押し出し造粒機により造粒し、乾燥
・解砕した後、■および■を混合し、打錠機にて圧縮成
型して一部200 mgの錠剤を得た。Example 3 ■ Crystalline cellulose 179 ■ 10% hydroxypropyl cellulose ethanol solution 259 ■ Carboxymethylcellulose calcium 2.79 ■ Magnesium stearate 0.396-shogaol 5 Total 509 According to the above recipe, ■, ■, and ■ were mixed uniformly. After the mixture was strung up using a conventional method, granulated using an extrusion granulator, dried and crushed, ■ and ■ were mixed, and the mixture was compressed using a tablet machine to obtain 200 mg tablets. .
この錠剤−錠には、(6)−ショウガオール20次9が
含有されており、成人1日1〜4錠を数回にわけて服用
する。This tablet contains (6)-shogaol 20-9, and adults should take 1 to 4 tablets a day in several doses.
実施例4
■コーンスターチ 439■ステアリン酸
マグネシウム 0.5g■カルボキシメチル
セルロースカルシウム 53
■軽質無水ケイ酸 0.59■ 6−ショウ
ガオール 19計 509
上記の処方に従って■〜■を均一に混合し、圧縮成型機
にて圧縮成型後、破砕機により粉砕し、篩別して顆粒剤
を得た。Example 4 ■Corn starch 439■Magnesium stearate 0.5g■Carboxymethylcellulose calcium 53 ■Light silicic anhydride 0.59■6-Shogaol 19 total 509 According to the above recipe, ■~■ were mixed uniformly and molded using a compression molding machine. After compression molding, the mixture was crushed using a crusher and sieved to obtain granules.
この顆粒剤19には、(6)−ショウガオール2019
が含有されており、成人1日1〜49を数回にわけて服
用する。This granule 19 contains (6)-shogaol 2019
It contains 1 to 49 doses per day for adults, divided into several doses.
実施例5
■結晶セルロース 299
■lO%ヒドロキシプロピル
セルロースエタノール溶液209
6−ショウガ −ル 19
計 509
上記の処方に従って■〜■を均一に混合し、ねつ和した
。押し出し造粒機に上り造粒後、乾燥し、篩別して顆粒
剤を得た。Example 5 (1) Crystalline cellulose 299 (10% hydroxypropylcellulose ethanol solution) 209 6-ginger 19 Total 509 Items (1) to (2) were uniformly mixed and slurried according to the above recipe. After going into an extrusion granulator and granulating, the mixture was dried and sieved to obtain granules.
この顆粒剤1gには、(6)−ショウガオール2019
が含有されており、成人1日1〜4gを数回にわけて服
用する。1 g of this granule contains (6)-shogaol 2019
It contains 1 to 4 g per day for adults, divided into several doses.
実施例6
■コーンスターチ 44.59■軽質無水ケイ
酸 0.5g3(6−ショウガオール
5g計 509
上記の処方に従って■〜■を均一に混合し、200π9
を2号カプセルに充填した。Example 6 ■Corn starch 44.59■Light silicic acid anhydride 0.5g3 (6-shogaol)
5g total 509 Mix ■~■ uniformly according to the above recipe, 200π9
was filled into a No. 2 capsule.
このカプセル剤lカプセルには、(6)−ショウガオー
ル20m9が含有されており、成人1日1〜4カプセル
を数回にわけて服用する。This capsule contains 20 m9 of (6)-shogaol, and adults should take 1 to 4 capsules a day in several doses.
実施例7
■注射用蒸留水 適量
■ブドウ糖 200119■(6−シ
ョウガオール l mg全全量
5−
注射用蒸留水に■および■を溶解させた後、5dのアン
プルに注入し、121 ’Cで15分間加圧滅菌を行っ
て注射剤を得た。Example 7 ■ Distilled water for injection Appropriate amount ■ Glucose 200119 ■ (6-shogaol l mg total amount
5- After dissolving ① and ② in distilled water for injection, they were injected into a 5d ampoule and autoclaved at 121'C for 15 minutes to obtain an injection.
実施例8
■(6)−ショウガオール 0.059■白色ワセ
リン 259■ステアリルアルコール
229■サラシミツロウ 159■
ポリオキシエチレン(25)
モノステアリン酸エステル2.39
■ソルビタンモノパルミテート2.79■パラオキシ
安息香酸プロピル 0.059
■パラオキシ
安息香酸メチル 0.059
上記の処方に従って■〜■を均一に混合し、加熱溶解し
て軟膏剤を得た。Example 8 ■(6)-Shogaol 0.059■White petrolatum 259■Stearyl alcohol
229 ■ White beeswax 159 ■
Polyoxyethylene (25) Monostearate 2.39 ■ Sorbitan monopalmitate 2.79 ■ Propyl paraoxybenzoate 0.059 ■ Methyl paraoxybenzoate 0.059 Mix ■ to ■ uniformly according to the above recipe, The mixture was heated and dissolved to obtain an ointment.
特許出願人 株式会社 津村順天堂Patent applicant: Tsumura Juntendo Co., Ltd.
Claims (1)
。(6) - A therapeutic agent for keratosis containing gingerol as an active ingredient.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25077687A JPH0228567B2 (en) | 1987-10-06 | 1987-10-06 | KATSUKASHOCHIRYOZAI |
KR1019890701011A KR920000892B1 (en) | 1987-10-06 | 1988-09-22 | Keratosis-treating agent |
AT88908350T ATE92756T1 (en) | 1987-10-06 | 1988-09-22 | MEANS FOR TREATMENT OF KERATosis. |
DE88908350T DE3883208T2 (en) | 1987-10-06 | 1988-09-22 | AGENTS FOR TREATING KERATOSIS. |
EP88908350A EP0334967B1 (en) | 1987-10-06 | 1988-09-22 | Keratosis-treating agent |
PCT/JP1988/000959 WO1989003376A1 (en) | 1987-10-06 | 1988-09-22 | Keratosis-treating agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25077687A JPH0228567B2 (en) | 1987-10-06 | 1987-10-06 | KATSUKASHOCHIRYOZAI |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0196121A true JPH0196121A (en) | 1989-04-14 |
JPH0228567B2 JPH0228567B2 (en) | 1990-06-25 |
Family
ID=17212874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP25077687A Expired - Lifetime JPH0228567B2 (en) | 1987-10-06 | 1987-10-06 | KATSUKASHOCHIRYOZAI |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0228567B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100902679B1 (en) * | 2007-12-10 | 2009-06-15 | 우석대학교 산학협력단 | Prepartaion of concentrated syrups for oral use containing alcohol fermentated extracts of zingiberis rhizoma and its compounding herbal medicines |
-
1987
- 1987-10-06 JP JP25077687A patent/JPH0228567B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100902679B1 (en) * | 2007-12-10 | 2009-06-15 | 우석대학교 산학협력단 | Prepartaion of concentrated syrups for oral use containing alcohol fermentated extracts of zingiberis rhizoma and its compounding herbal medicines |
Also Published As
Publication number | Publication date |
---|---|
JPH0228567B2 (en) | 1990-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0543469A (en) | Beta-glucuronidase inhibitor | |
JPH02193930A (en) | Radical eliminating agent | |
JPH03271227A (en) | Therapeutic agent for treating diabetes mellitus | |
KR920000892B1 (en) | Keratosis-treating agent | |
JPH01207233A (en) | Antiarteriosclerotic | |
JP2540871B2 (en) | Antihyperlipidemic agent | |
JPH0196121A (en) | Remedy for hyperkeratosis | |
JPH01254625A (en) | Anti-allergic agent | |
JP2629844B2 (en) | Antiparasitic agent | |
JPH0368516A (en) | Na+,k+-atpase inhibitor | |
JPH0717859A (en) | Arachidonic acid dysbolism disease therapeutic agent | |
JPH02264722A (en) | Anticancer agent | |
JP2821575B2 (en) | Liver disorder improving agent | |
JPH06172195A (en) | Udp-glucuronyl transferase inhibitor | |
JPH01233217A (en) | Remedy for diabetes | |
JPH01294621A (en) | Stem cell propagation promoter | |
JPH0717857A (en) | Circulatory disease therapeutic agent | |
JPH0717507B2 (en) | Antithrombotic agent | |
JPH01224367A (en) | Polyacetylene compounds and 5-lipoxygenase inhibitor containing polyacetylene compounds as active component | |
JPH03215418A (en) | Carcinogenesis suppressing agent | |
JPH01207256A (en) | Novel cis-(6)-shogaol and remedy for hyperkeratosis containing said compound as active ingredient | |
JP2541231B2 (en) | Novel compound and platelet aggregation inhibitor containing the compound as an active ingredient | |
JPH06183988A (en) | Preventive for bladder cancer | |
JPS60184017A (en) | Tonic agent | |
JPH04208222A (en) | Anti-inflammatory and antiallergic agent |